Study explains why certain immunotherapies don't always work as predicted | MIT News | Massachusetts Institute of Technology
An MIT study reveals a possible explanation for why checkpoint blockade inhibitors don’t work well for some patients whose tumors have a high mutational burden.
Source: mit.edu